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ACE – angiotensin-converting enzyme 
ACS – acute coronary syndrome 
ACT – activated clotting time 
ADP – adenosine diphosphate 
AMI – acute myocardial infarction 
aPTT – activated partial thromboplastin time 
ARBs – angiotensin receptor blockers 
AUC – area under the curve aggregation units 
BMI – body mass index 
CABG – coronary bypass graft surgery 
CAD – coronary artery disease 
CrCl – creatinine clearance 
DAPT – dual antiplatelet therapy 
EF – ejection fraction 
GPI – Glycoprotein IIb/IIIa 
HPR – high on-treatment platelet reactivity 
IQR – interquartile range 
LMWH – low molecular weight heparin 
LTA – light transmission aggregometry 
LV – left ventricle/ventricular 
MACE – major adverse cardiovascular events 
MEA – multiple electrode aggregometry 
MI – myocardial infarction 
NACE – net adverse clinical events 
NSTE-ACS – non-ST-elevation acute coronary syndrome 
NSTEMI – non-ST-elevation myocardial infarction 
PCI – percutaneous coronary intervention 
PRP – platelet-rich plasma 
ROC – receiver operating characteristic 
SD – standard deviation 
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STEMI – ST-elevation myocardial infarction 
TIMI – thrombolysis in myocardial infarction 
UA – unstable angina 
































Coronary artery disease (CAD) is the major cause of mortality in developed 
countries (Perk et al., 2012). It is caused by atherosclerosis which results in 
occlusion of coronary arteries. This causes imbalance in request of blood 
supply and its availability. Under stress conditions, with higher demand on 
oxygen, it manifests as stable angina pectoris. In the case of rupture of unstable 
atherosclerotic plaque with sudden occlusion of coronary vessels, acute 
coronary syndrome (ACS) occurs. Cardiac catheterization with coronary 
angiography is used to diagnose the extent of the disease and allows to treat 
coronary lesions by percutaneous transluminal coronary angioplasty (PTCA) 
usually followed by coronary stent implantation, if necessary. This procedure 
relieves symptoms in stable patients and lowers mortality in patients with ACS. 
Antithrombotic therapy is an important part of management in patients with 
CAD. Anticoagulants inhibiting plasma coagulation system and antiplatelet 
agents acting against platelet aggregation are used.  
 
Blood platelets play a crucial role for thrombus formation in ACS. Antiplatelet 
drugs inhibit their activation and reduce the risk of myocardial infarction (MI) 
and stent thrombosis. Dual antiplatelet therapy is prescribed for a particular time 
after percutaneous coronary intervention (PCI) to prevent stent thrombosis. In 
long-term treatment of patients with CAD single antiplatelet treatment lowers 
ischemic events and reduces mortality (Antiplatelet Trialists’ Collaboration, 
1994). Anticoagulants act against thrombus-formation through the inhibition of 
thrombin generation or activity and thus reduce thrombus formation and 
myocardial ischemia in the setting of ACS. Importantly, they are also necessary 
during elective PCI to prevent catheter associated thrombosis. On the other 
hand, it increases bleeding risk. Risk stratification of patients with CAD 
undergoing PCI is, therefore, necessary to find the best balance between risk 




1.1 Overview and brief characteristics of antithrombotic drugs used in 
patients with CAD 
 
1.1.1 Antiplatelet therapy 
 
Aspirin 
Aspirin (acetylsalicylic acid) acts through irreversible acetylation of 
cyclooxygenase-1. This enzyme blocks catalysis of arachidonic acid to 
prostaglandin G2; and further, the formation of thromboxane-A2, which is a 
potent activator of platelet aggregation. As the inhibition of platelets is 
irreversible, it blocks platelet function for the rest of their lifetime in circulation 
(about 10 days). Aspirin is characterized by fast resorption and acts already 
after 10-20 minutes after oral application. The usual dose for the therapy of 
coronary artery disease is 75-100 mg once daily. In patients with ACS bolus 




Clopidogrel is a thienopyridine derivate which irreversible inhibits the P2Y12-
receptor receptor. It prevents binding of ADP on the receptor which is a potent 
platelet activator. Clopidogrel is a prodrug and has to be activated to its active 
metabolite (a thiol derivative of clopidogrel). This takes place in liver, in two 
steps mediated by cytochrome-P450-enzyme. Full therapeutic effect occurs 
with a delay of circa 30-60 Minutes after oral application. Clopidogrel is given in 
a dose of 75 mg/day. Loading dose of 600 mg is used to achieve fast and 
sufficient platelet inhibition (Droppa and Geisler, 2013). 
 
Prasugrel 
Prasugrel is a novel P2Y12-receptor inhibitor. Similarly to clopidogrel it is a 
thienopyridine derivate, that inhibits platelets through ADP. Prasugrel is also a 
prodrug, but it needs only one-step biotransformation leading to much faster 
transformation compared to clopidogrel, allowing a therapeutic effect already 
10 
 
after 30 minutes. The usual treatment-dose is 10 mg pro day, the loading dose 
is 60 mg (Droppa and Geisler, 2013). 
 
Ticagrelor 
Ticagrelor is a nucleoside analogue, and it has a structural similarity to 
adenosine. Similarly to thienopyridines it blocks the P2Y12-receptor and hence 
ADP-dependent pathway of platelet aggregation. In contrast to clopidogrel and 
prasugrel, the binding site for ticagrelor is different from ADP, and the blockage 
is reversible. It does not require the biotransformation from a prodrug. Its effect 
onsets 30 minutes after oral application. The usual treatment-dose is 90 mg 
twice a day, the loading dose is 180 mg (Droppa and Geisler, 2013). 
  
Glycoprotein IIb/IIIa-Inhibitors 
Platelet glycoprotein IIb/IIIa receptor allows binding of activated platelets to 
fibrinogen and hence platelet aggregation. Glycoprotein IIb/IIIa-inhibitors (GPI) 
block this pathway. There are three substances currently available – abciximab, 
tirofiban and eptifibatide. They differ in chemical structure and duration of their 
antiplatelet effect. Abciximab is a monoclonal antibody against GP IIb/IIIa 
receptor with a dissociation half time of 12-24 hours, tirofiban is  a non-peptide 
antagonist with  plasma lifetime of 2 hours and eptifibatide a synthetic peptide 
antagonist with lifetime of 2-2.5 hours (Bennett, 2001). All substances are 
administered intravenously. They are usually administered as a bail-out therapy 
in patients with ACS undergoing PCI, they are given periinterventionally and for 
12-24 hours as continuous intravenous infusion after PCI. The dose is adjusted 
to weight and renal function. 
 
Cangrelor 
Cangrelor is a novel intravenous short acting P2Y12-receptor inhibitor available 
for use in patients undergoing PCI. Possible advantages are an immediate 
onset of platelet inhibition in comparison to oral P2Y12-receptor inhibitors and its 
short half time (minutes) allowing immediate stopping of the therapy in case of 
bleeding complications or necessary surgical intervention. Weight adjusted 
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dose is administered intravenously, as a bolus, followed by continuous infusion 
(Droppa and Geisler, 2013). 
 
1.1.2 Anticoagulants  
 
Unfractionated heparin 
Unfractionated heparin (UFH) is a mixture of glycosaminoglycans in different 
molecular weight which inhibit thrombin through activation of antithrombin III. It 
is administered intravenously, as a bolus of 60-70 IU/kg, followed by an infusion 
of 12-15 IU/kg/h. Due to its interindividual variability and a narrow therapeutic 
window, monitoring using activated partial thromboplastin time (aPTT) or 
activated clotting time (ACT) is necessary. Half time of heparin is short, and the 
antagonist protamine is available making easy to antagonize anticoagulant 
effect in case of bleeding. Therapeutic dose should be titrated to achieve 1.5-
2.5 times the upper normal limit of aPTT (50-75 s). During PCI ACT is used to 
control the dose of heparin. A higher bolus during PCI (70-100 IE/kg) is used, 
an ACT 250-350 s is intended when no glycoprotein IIb/IIIa inhibitors (GPI) are 
used. In case of combination with GPI inhibitors, a bolus of 50-70 IU/kg and 
target ACT of 200-250 s is used to guide the therapy (Authors/Task Force 
members et al., 2014). 
 
Low molecular weight heparins and fondaparinux 
Low molecular weight heparin (LMWH) is produced by depolymerization of UFH 
to molecular weight lower than 8000 Da. In contrast to UFH which inhibits both 
thrombin and factor Xa, LMWH inhibits factor Xa relatively selectively. It has 
much longer half time in plasma and more predictable pharmacokinetics. From 
many available LMWH, enoxaparin is approved for treatment of patients with 
ACS (Silvain et al., 2012a). It is dosed adjusted to body weight and renal 
function and administered subcutaneously or intravenously (periinterventional). 
Fondaparinux has similar anticoagulant effects  compared to LMWH but lower 
bleeding risk  (Fifth Organization to Assess Strategies in Acute Ischemic 
Syndromes Investigators et al., 2006). It is a synthetic pentasaccharide which 
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selectively inhibits factor Xa by antithrombin without inhibiting thrombin. It is 
recommended in patients with unstable angina (UA) and non-ST-elevation 
myocardial infarction (NSTEMI) in dose of 2.5 mg/day. 
 
Bivalirudin 
Bivalirudin is a synthetic peptide similar to hirudin. It reversibly inhibits thrombin 
both circulating and clot-bound. Advantages of bivalirudin are better predictable 
pharmacodynamics and pharmacokinetics than heparin. In contrast to heparin, 
it doesn’t induce but inhibits platelet activation. In randomized studies bivalirudin 
reduced the risk of bleeding complications in comparison to heparin with GPI in 
patients with ST-elevation myocardial infarction (STEMI) and NSTEMI (Stone et 
al., 2006, 2011). 
 
1.2 Use of antithrombotic substances in patients undergoing PCI 
 
1.2.1 Dual antiplatelet therapy 
 
After implantation of coronary stents dual antiplatelet treatment with aspirin and 
P2Y12-receptor inhibitor is prescribed to prevent ischemic complications such as 
stent-thrombosis and recurrent myocardial infarction (MI). The most used 
P2Y12-receptor inhibitor is clopidogrel, however significant interindividual 
variability of platelet inhibition exists due to its pharmacokinetics. Genetic 
factors especially in metabolizing of clopidogrel (variability in cytochrome P450 
enzyme) are responsible. Other possible reasons are variability in intestinal 
absorption and interaction with other drugs. Patients with high on-treatment 
platelet reactivity (HPR) and hence reduced response to clopidogrel have 
significant higher rate of major adverse cardiovascular events after PCI (Geisler 
et al., 2006). 
 
Novel P2Y12-receptor inhibitors prasugrel and ticagrelor have advantage over 
clopidogrel through better platelet inhibition and lower interindividual variability. 
Using novel P2Y12-inhibitors frequency of low-responders could be reduced. 
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Ticagrelor and prasugrel showed better platelet inhibition and reduction of 
ischemic adverse events in patients with ACS. Ticagrelor even lowered overall 
mortality in the PLATO study (Wiviott et al., 2007; Wallentin et al., 2009). Based 
on two large randomized studies (TRITON-TIMI-38 and PLATO) prasugrel and 
ticagrelor are recommended as first choice therapy in patients with ACS. 
Bleeding risk under prasugrel and ticagrelor seems to be slightly higher than 
under clopidogrel. Patients above 75 years, with body weight less than 60 kg 
and with a history of stroke were at higher risk for bleeding events in prasugrel 
treated patients. Thus, ticagrelor or clopidogrel should be the preferred option in 
these patients (Authors/Task Force members et al., 2014; Wiviott et al., 2007). 
Further, patients under oral anticoagulants shouldn’t be treated with prasugrel 
and ticagrelor in combination with aspirin due to higher bleeding risk. 
 
Whereas ticagrelor and prasugrel are now largely used in patients with ACS, 
clopidogrel is still recommended in patients with stable coronary disease. There 
are no large clinical randomize studies comparing clopidogrel with ticagrelor or 
prasugrel in low-risk patients with stable coronary disease. As mentioned 
above, however significant proportion of such patients may have lower 
response to clopidogrel and hence higher risk of adverse ischemic events. 
Identification of these patients could help to tailor antiplatelet treatment with 
more potent antiplatelet drugs. 
 
1.2.2 Anticoagulants in patients undergoing PCI 
 
In patients with ACS acute myocardial ischemia is caused by unstable 
atherosclerotic plaque with formation of thrombus and its embolization or total 
vessel occlusion. Anticoagulants inhibit thrombin formation and hence act again 
progression of present thrombus and reduce the extent of myocardial ischemia. 
Anticoagulants are indicated in patients with ACS immediate after establishing 
the diagnosis and are given continuously in the periprocedural phase during 
PCI. Also in elective coronary intervention in patients with stable coronary 
disease an effective anticoagulation is necessary to prevent intravascular and 
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catheter associated thrombus formation. Variety of substances are approved for 
periinterventional anticoagulation. For elective PCI in stable coronary disease 
UFH is recommended, in patients with high bleeding risk bivalirudin should be 
considered according to current guidelines (Authors/Task Force members et al., 
2014). In patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) 
UFH, enoxaparin, fondaparinux or bivalirudin are recommended whereas the 
latter both were associated with lower bleeding events. In patients with STEMI 




1.3.1 Risk stratification of patients with stable angina pectoris and dual 
antiplatelet therapy 
 
High on-treatment platelet reactivity is common in patients treated with 
clopidogrel. It was shown that these patients have worse prognosis (Geisler et 
al., 2006). Several clinical risk factors were associated with HPR in patients 
treated with clopidogrel (Geisler et al., 2008). Aim of our study was to evaluate 
clinical risk factors which predispose to HPR in patients with stable angina 
pectoris. We evaluated clinical characteristics of consecutive patients admitted 
with stable angina pectoris and treated by PCI. Platelet reactivity was measured 
in all patients. Identification of the clinical risk factors would allow to predict 
patients with HPR and hence at risk of ischemic cardiac events. For these 
patients intensified antiplatelet treatment e.g. with prasugrel or ticagrelor could 
be considered to improve the prognosis. 
 
1.3.2 Individual antiplatelet treatment according to platelet function 
analysis in clinical praxis 
 
Large interindividual variability in response to antiplatelet therapy mainly 
clopidogrel raise a question of relevance of platelet function testing in clinical 
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practice. Several assays are commercially available to test platelet aggregation 
under antiplatelet treatment after stimulation by ADP. Routine testing of 
clopidogrel response is not recommended, however there are several clinical 
situations when testing of response is helpful to manage the patients.  In our 
case report we present such a case of a patient with short-bowel syndrome and 
discuss pharmacokinetics and pharmacodynamics of antiplatelet substances in 
patients with intestinal malabsorption syndrome. 
 
1.3.3 Optimal periinterventional anticoagulation in patients with NSTEMI 
undergoing PCI and its bleeding risk 
 
Anticoagulation therapy is indicated in all patients after establishing of the 
diagnosis of NSTEMI. UFH, LMWH, fondaparinux and bivalirudin are approved 
for this indication. There were several studies which were performed to find 
optimal strategy for anticoagulation. An important aspect is the safety of 
anticoagulants in view of possible bleeding complications, which are enhanced 
due to combination with oral antiplatelet therapy and GPI. From the above 
therapies bivalirudin was proved to have very low bleeding risk in comparison 
with heparin in combination with GPI. According to current guidelines PCI 
should be performed within 24 hours in patients with intermediate risk. The 
impact of anticoagulation regime dependent on time from diagnosis to PCI has 
not been systematically studied so far. We therefore sought to analyze the 
impact of different antithrombotic regimens to clinical events in patients with 
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3. Discussion 
 
Antithrombotic therapy is an important part of treatment for patients with CAD 
undergoing PCI. It reduces ischemic complications and improves prognosis. In 
our work we evaluated specific aspects of choosing the appropriate 
antithrombotic treatment. First, we evaluated clinical risk predictors for HPR in 
patients with stable CAD. We developed a risk score, which allows to identify 
patients with higher risk for HPR and MACE. Second, we discussed clinical 
indications of individual platelet aggregation testing in a case-report of a 
challenging patient with a malabsorption syndrome. Finally, we evaluated 4 
anticoagulation regimens in patients with NSTEMI during medical phase of 
treatment prior to revascularization. Risk stratification of patients according to 
clinical characteristics helps to find the best individual treatment under 
consideration of the efficacy-safety profile of the chosen agent. 
 
3.1 Risk stratification of patients with stable angina pectoris treated 
with dual antiplatelet treatment after PCI 
 
After PCI dual antiplatelet therapy is necessary to prevent adverse cardiac 
events such as stent thrombosis. However, interindividual variability in response 
to clopidogrel remains a challenging clinical problem. Patients after PCI with 
HPR have worse prognosis, regarding ischemic cardiac events, than patients 
with sufficient platelet inhibition (Geisler et al., 2006). Platelet function testing 
allows identification of non-responders, however, its routinely administration 
failed to improve outcome in some clinical trials, likely due to low-risk studied 
population (Price et al., 2011; Collet et al., 2012; Trenk et al., 2012). Further, 
clinical risk stratification may be a useful tool to identify patients at high-risk for 
HPR, and so a means of predicting clinical adverse events. We evaluated 
clinical characteristics, platelet function and clinical events after 12 month of 
follow up in 739 patients with stable coronary disease undergoing PCI. In our 
study, age, adiposity, diabetes mellitus, reduced renal function and reduced left 
ventricular function were associated with HPR. Accordingly, we have developed 
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a risk score depending on effect size of the clinical variables on HPR – 
PREDICT-STABLE Score, ranging from 0 to 9. We could show that patients 
with higher score (7-9) had significant higher MACE in 12 month of follow up 
(10.3% versus 3.4% in patients with score 0-3). We have validated these 
findings on an independent cohort of patients with stable coronary disease. This 
simple score allows to identify patients at higher risk, who may profit from more 
intensive antiplatelet therapy i.e. prasugrel or ticagrelor. 
 
3.2 Individual antiplatelet therapy in selected patients in clinical praxis 
 
Despite variable response rates to antiplatelet therapy mainly under clopidogrel 
medication, measuring of platelet function was not established routinely in 
patients undergoing PCI. However, in clinical practice the testing of platelet 
response can be sometimes crucial for appropriate therapy. In our case report, 
we could show an example of a difficult clinical situation during treatment of a 
patient with malabsorption due to short-bowel syndrome. The efficacy of the 
medication, in such cases, is not simply predictable due to reduced absorption 
surface of the intestine, and pharmacological testing may be warranted. In our 
patient there was reduced response to both clopidogrel and prasugrel. The 
reason for that are specific pharmacokinetics and metabolism of these drugs 
with an important involvement of intestinal mucosa as discussed above. The 
best choice for our patient was the therapy with ticagrelor, which doesn´t need 
metabolic transformation to active metabolite and is very good absorbed from 
intestinal tract. These findings could be transferred to similar patients with 
malabsorption syndrome and could help to choose the best antiplatelet therapy. 
 
There are more possible indications of platelet response testing in clinical 
practice. First, patients under clopidogrel treatment after PCI with high risk, 
such as stentthrombosis in medical history, diabetes mellitus or performed 
complex coronary interventions e.g. left main PCI or long stent lesions, could be 
considered for platelet reactivity testing.  Second, patients with unpredictable 
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pharmacokinetics such as massive adiposity, liver or intestinal diseases could 
also profit from platelet aggregation testing. 
 
3.3 Anticoagulation in patients with NSTEMI 
 
Anticoagulation is necessary during medical treatment period in patients with 
NSTEMI as it inhibits thrombin generation and reduces ischemic events. On the 
other hand, it is associated with increased bleeding risk. Bleeding is associated 
with increased mortality in patients with NSTEMI necessitating balanced 
anticoagulation treatment (Manoukian et al., 2007; Doyle et al., 2009). We 
investigated anticoagulation regimes in patients with NSTEMI during medical 
treatment before PCI. We could show that bivalirudin had the best net clinical 
benefit of all studied combinations – heparin, heparin plus GPI and bivalirudin 
plus GPI. This difference was mainly driven by lower bleeding risk.  
 
Bivalirudin binds directly to thrombin and inhibits both circulating and clot-bound 
thrombin. Moreover, in contrast to heparin it doesn´t activate but inhibits 
platelets. It has more predictable pharmacokinetics in comparison to UFH. 
Bivalirudin was shown to reduce bleeding risk in several randomized clinical 
trials. In patients with STEMI it reduced bleeding events by comparable MACE 
in HORIZONS-AMI (Stone et al., 2008, 2011), EUROMAX (Steg et al., 2013) 
and BRIGHT (Han et al., 2015) trials. The same could be shown in patients with 
NSTEMI in ACUITY (Stone et al., 2006, 2007b) and ISAR-REACT 4 (Kastrati et 
al., 2011) trials where patients treated with bivalirudin had lower bleeding rates 
with comparable MACE. Direct comparison of UFH and bivalirudin was 
investigated in ISAR-REACT 3 (Kastrati et al., 2008) and HEAT-PPCI (Shahzad 
et al., 2014) trials. In ISAR-REACT 3 trial, patients with stable CAD and 
biomarker negative ACS were randomized. Bivalirudin showed comparable 
ischemic events and mortality but lower bleeding risk. In the HEAT-PPCI there 
was no difference in bleeding events between UFH and bivalirudin, however, 
bivalirudin was associated with higher catheter thromboembolic events in 
patients with STEMI undergoing primary PCI. Another trial MATRIX included 
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patients with STEMI and NSTEMI, it showed reduced bleeding events and 
slightly higher rate of stentthrombosis in bivalirudin arm. Our analysis adds 
knowledge to upstream anticoagulant treatment of NSTEMI patients. It shows 
that bivalirudin has a good safety profile during medical phase of treatment 
according to bleeding events which is in line with previous studies. It implicates 
that bivalirudin should be considered in patients with higher bleeding risk. 
 
3.4 Implication of the findings for praxis 
 
According to current guidelines novel P2Y12-receptor inhibitors i.e. prasugrel 
and ticagrelor are first-line therapy for patients with ACS. Prasugrel was 
clinically tested in large TRITON-TIMI-38 trial, stentthrombosis and MI were 
significantly reduced in comparison with clopidogrel. Similarly, PLATO trial 
showed that patients treated with ticagrelor have reduced ischemic events 
(death, MI, ischemic stroke) and reduced mortality. Explanation of these 
findings are better pharmacokinetics and pharmacodynamics of those drugs 
allowing better predictable effect, higher platelet inactivation and less 
interindividual variability. In patients with stable angina pectoris who are in lower 
risk clopidogrel is still recommended. However, interindividual variability of 
metabolism of clopidogrel and hence significant proportion of non-responders 
may be problematic in some patients. Till now, large randomized clinical trials 
comparing clopidogrel and novel P2Y12-recetor inhibitors in patients with stable 
angina pectoris are missing. Thus, individual clinical risk stratification may help 
to identify patients who would profit from more intensive antiplatelet treatment. 
In our work, we could identify several clinical variables and develop a score 
which could help to identify patients at higher risk for adverse ischemic events. 
Patients with higher score levels had significant worse prognosis measured by 
MACE. Mainly patients with diabetes mellitus, adiposity, renal- and heart-failure 
could be considered to more intensive treatment. Except these factors 
interventional aspects of PCI should be taken to account, i.e. patients with long 
stents lesions with higher risk of stent thrombosis or patients after left main PCI 
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are also possible candidates to more potent antiplatelet treatment. Alternatively, 
individual platelet aggregation testing may be performed. 
 
Direct measuring of platelet aggregation remains indicated in special clinical 
conditions. We could show one example where individual platelet reactivity 
testing offered advantage to standard therapy. In our patient with short-bowel 
syndrome, drug absorption and effectiveness was questionable due to 
massively reduced intestinal mucosa after extensive intestine resection. Even 
use of novel high effective P2Y12-receptor inhibitor prasugrel didn’t show an 
expected effect. Using of platelet testing allowed to manage medical therapy 
and prevent ischemic events. Patients with similar clinical problems such as 
unpredictable pharmacodynamics and pharmacokinetics or patients at high risk 
for ischemic events may be considered for individual platelet aggregation 
testing. 
 
Anticoagulation prior and during PCI inhibits thrombin formation and hence 
prevents progression of ischemia and trombusformation on catheter devices. In 
stable patients with NSTEMI, general recommendations allow for up to 24 hours 
of conservative medical therapy until angiography and subsequent triage to 
PCI, CABG or medical therapy. During the upstream treatment period 
anticoagulants are indicated to inhibit thrombin generation and platelet 
activation. Variety of anticoagulation agents are approved in patients with 
NSTEMI prior and during PCI. Probably, the most common is the UFH because 
of its availability, short plasmatic half-life, low cost and broad experience with its 
use under medical professionals. Alternatively, bivalirudin can be used. 
Bivalirudin is direct thrombin inhibitor which was extensively tested in large 
randomized trials and has been shown to have low risk of bleeding. We 
evaluated bleeding and ischemic events in the upstream period and could show 
that bivalirudin significantly reduces bleeding in comparison with UFH with or 
without GPI. This is in line with other studies and indicates that bivalirudin 
should be preferred in patients with higher bleeding risk. Fondaparinux and 
enoxaparin are further options of anticoagulation prior to PCI. Fondaparinux has 
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very good safety profile according to bleeding events. However, it has long 
elimination half-life (17 hours) and no available antagonist, which can be 
problematic in case of urgent coronary bypass surgery or bleeding 
complications. Other strategies mainly use of radial access for catheterization 




Antithrombotic therapy is an important part of management in patients with CAD 
undergoing PCI. It prevents thrombus progression and hence reduces ischemia 
in patients with ACS. During coronary intervention it protects against thrombus 
formation on used devices such as coronary catheters, balloons and stents. 
After stent deployment dual platelet therapy prevents stentthrombosis till 
endothelialisation process of the implanted device is finalized. However, 
antithrombotic agents are associated with an increased risk of bleeding, 
necessitating balancing their risks and benefits.  Risk stratification of patients is 
crucial to decide which antithrombotic therapy is the best option for individual 
patient. 
 
After PCI dual antiplatelet therapy with aspirin and P2Y12-receptor inhibitor is 
indicated. Novel P2Y12-receptor inhibitors i.e. ticagrelor and prasugrel are first-
line therapy for patients with ACS. Better platelet inhibiting effect, lower 
interindividual variability in response to the therapy and reduction of ischemic 
events was proved in large randomized control trials. Clopidogrel is 
recommended for patients with stable angina pectoris. There is a high 
interindividual variability of response to clopidogrel, whereas lower response 
predisposes to higher rate of ischemic events. We could show that HPR could 
be predicted by distinct clinical variables and developed a PREDICT-STABLE 
Score which helps to identify patients in risk for MACE. We could validate the 
score in an independent cohort of patients. Patients at high risk could be 





Platelet reactivity testing allows to evaluate individual response to antiplatelet 
treatment. This tool could be used in selected high-risk patients to guide the 
therapy. In our case-report we could prove this concept of individual therapy in 
high-risk patient with extended malabsorption after intestine resection. We could 
show that ticagrelor, because of its favorable pharmacokinetics, was the best 
choice for effective P2Y12-receptor inhibition in this clinical setting. 
 
There are several options of approved anticoagulation in patients with NSTEMI 
during medical therapy before revascularization. We analyzed data of large 
randomized clinical trial (ACUITY) on ischemic and bleeding rates during 
medical therapy. We compared four anticoagulation regimes – UFH alone, UFH 
plus GPI, bivalirudin alone and bivalirudin plus GPI. We could show that 
bivalirudin alone has the lowest bleeding events by similar rates of ischemic 
events, and hence the best net clinical benefit during medical treatment before 
PCI. This should be taken into account when choosing the treatment of 




Die antithrombotische Therapie ist ein wichtiger Teil des Managements bei 
Patienten mit koronarer Herzerkrankung. Sie verhindert die 
Thrombusprogression und reduziert damit die Ischämie bei den Patienten mit 
einem akuten Koronarsyndrom. Während der koronaren Intervention verhindert 
die antithrombotische Therapie eine Thrombusformation auf den benutzten 
Kathetern, Ballons und Stents. Zur Verhinderung der Stentthrombose wird nach 
der koronaren Intervention die duale Plättchenhemmung bis zum Abschluss der 
Stentendothelialisierung fortgeführt. Die antithrombotische Therapie ist jedoch 
mit einem erhöhten Blutungsrisiko assoziiert. Deshalb ist es notwendig, Nutzen 
und Risiko bei jedem Patienten sorgfältig abzuwägen. Klinische 
Stratifizierungen des Risikos ermöglichen die individuelle Entscheidung für die 




Nach der koronaren Intervention ist eine duale Plätchenhemmung mit 
Acetylsalicylsäure und P2Y12-Receptor Inhibitor indiziert. Bei den Patienten mit 
einem akuten Koronarsyndrom werden in der ersten Linie die neuen P2Y12-
Receptor Inhibitoren – Ticagrelor und Prasugrel eingesetzt. In den großen 
randomisierten Studien konnte hier ein Vorteil bezüglich einer besseren 
Plättcheninhibition, niedrigerer interindividueller Variabilität in der Wirkung, 
sowie Reduktion von ischämischen Ereignissen gezeigt werden. Bei den 
Patienten mit stabiler Angina pectoris wird Clopidogrel empfohlen. Die 
Patienten unter Clopidogreltherapie weisen jedoch eine hohe interindividuelle 
Variabilität in der Plätchenhemmung auf. Die Patienten mit verminderter 
Plätchenhemmung sind für ischämische Folgeereignisse prädisponiert. Wir 
konnten zeigen dass die hohe Plättchenreaktivität unter Clopidogreltherapie bei 
den Patienten mit stabiler Angina pectoris von verschiedenen klinischen 
Faktoren beeinflusst wird. Wir entwickelten den PREDICT-STABLE Score. 
Dieser hilft die Patienten mit erhöhtem ischämischem Risiko zu identifizieren. 
Ebenso, validierten wir den Score in einer unabhängigen Patientenpopulation. 
Patienten mit erhöhtem Risiko können von einer intensivierten 
plättchenhemmenden Therapie, z.B. mit neuen P2Y12-Receptor Inhibitoren 
profitieren. 
  
Plättchenaggregationstests ermöglichen die Evaluation des individuellen 
Ansprechens auf die plättchenhemmende Therapie. Sie können bei selektierten 
Hochrisikopatienten zur Steuerung der Therapie eingesetzt werden. In unserem 
Fallbeispiel zeigen wir die Bedeutung dieses Konzeptes bei einem Patienten mit 
ausgeprägter Malabsorption nach Darmresektion. Dank seiner günstigen 
Pharmakokinetik war Ticagrelor der überlegene P2Y12-Receptor Inhibitor für 
eine effektive Plätchenhemmung in dieser anspruchsvollen klinischen Situation. 
  
Mehrere Antikoagulantien sind für Patienten mit NSTEMI vor der 
Revaskularisation zugelassen. Wir haben die Daten einer großen 
randomisierten klinischen Studie (ACUITY) in Bezug auf Blutungsrisiko und 
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ischämische Ereignisse analysiert. Wir haben 4 Antikoagulationsregime 
(unfraktioniertes Heparin mit und ohne Glycoprotein IIb/IIIa-Inhibitoren sowie 
Bivalirudin mit und ohne Glycoprotein IIb/IIIa-Inhibitoren) verglichen. Während 
der medikamentösen Therapie zeigte Bivalirudin alleine die niedrigste 
Häufigkeit von Blutungskomplikationen ohne die ischämischen Ereignisse zu 
erhöhen. Bivalirudin sollte daher vor allem bei NSTEMI-Patienten mit erhöhtem 
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